AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment

AngioDynamics, Inc. (ANGO) recently announced the FDA 510(k) clearance for its AlphaVac F1885 System for the treatment of pulmonary embolism (PE).The application of the AlphaVac F1885 System in the non-surgical excision of thrombi or emboli from the venous vasculature is increased by the enhanced FDA indication, which permits the system to be used for PE therapy. By lowering the thrombus burden and enhancing right ventricular function, the indication broadens the range of therapy alternatives available to P ...